Ranolazine Brings Relief for Patients with Chronic Angina and Type 2 Diabetes


ranolazineRanolazine shined at the American College of Cardiology’s 62nd Annual Scientific Session in Mid-March 2013 when data from a phase 4 study, coined TERISA revealed positive findings. Known as the brand name Ranexa, Ranolazine is an efficacious treatment for chronic angina. The TERISA study, standing for Type 2 Diabetes Evaluation of Ranolazine In Subjects With Chronic Stable Angina, evaluated the addition of Ranolazine to current therapy for angina in patients with both type 2 diabetes and chronic angina. Significant relief was found by the patients who were dosed with Ranolazine, as they experienced a sizable reduction in the frequency of their angina episodes, as compared to the group of patients who were given a placebo. The high prevalence of patients with type 2 diabetes and angina led researchers to complete this investigative study, in the hopes that they would determine a safe and effectual treatment for this patient population.

The study involved 927 patients, who were randomized to receive either 500 milligrams of Ranolazine twice a day, which was titrated to a twice daily dose of 1000 milligrams on the eighth day, or a placebo pill. All patients continued to receive the optimal standard of care and current antianginal therapy for the duration of this study. During the second through the eighth weeks the group of patients who received Ranolazine experienced less frequency of angina attacks as compared to the placebo group of patients- (3.8 [3.6-4.1] compared to 4.3 [4.0-4.5] episodes. These statistics are encouraging for the patients with type 2 diabetes that experience the severe and debilitating pain of chronic angina.  Patients with a history of personal or family history of Long QT syndrome are not candidates for treatment with Ranolazine. The use of grapefruit products is not suggested for patients who are being treated with Ranolazine. Adverse effects are uncommon, and mild side effects can include dizziness, ear ringing, headache nausea and dry mouth. Ranolazine can be administered alongside many beta-blockers, calcium channel blockers, nitrates, angiotensin receptor blockers and ACE inhibitors.

The patent for Ranexa expires on May 27, 2019.  LGM Pharma provides Ranolazine, CAS number 142387-99-3, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

References:

www.gilead.com

Business Wire, Presented at Late-Breaking Clinical Trial Session at the American College of Cardiology’s Annual Scientific Session. March 10, 2013

Bullets:

Ranolazine shined at the American College of Cardiology’s 62nd Annual Scientific Session in Mid-March 2013 when data from a phase 4 study coined TERISA revealed positive findings.

Known as the brand name Ranexa, which has a patent expiration of May 27, 2019, Ranolazine is an efficacious treatment for chronic angina.

The TERISA study, standing for Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina, evaluated the addition of Ranolazine to current therapy for angina in patients with both type 2 diabetes and chronic angina.

  • Share: